CTN funding for Phase III will be added in 2019.
Table 1. NIH, State, and Foundation grants received with the assistance of one or more CTN Core Facilities.
Principal Investigator(s) Department | Agency | Title | Dates Total award $. All years |
M. Aitken, M.D. Pediatrics | CDC | Strike out passenger injury | 02/07-01/10 749,963 |
“ | DHHS | Development and Evaluation of Targeted ATV Safety Educational Strategies for Rural Children | 09/07-08/10 549,642 |
“ | ACH | Pediatric Injury Prevention Center | 07/07-06/10 741,000 |
“ | Allstate | Building consensus for safer teen driving | 08/07-07/08 49,997 |
“ | AR Dept Tran | Mapping the way to success toolkit & guide | 12/07-11/11 472,378 |
“ | NHTSA | Improving Teen Driving through Parental Responsibility | 09/09-08/11 600,000 |
“ | HSO | Child Passenger Safety Education Project | 10/10-09-11 190,000 |
“ | NIH-NICHD subcon | Safety in Seconds 2.0 (A. Gielen PI) | 04/12-03/17 286,290 |
“ | NIH-NICHD subcon | Neurobehavioral Outcome of Head Injury in Children (H. Levin PI) | 08/12-07/13 27,500 |
E. Al-Chaer, Ph.D. Pediatrics | NIH-NIDDK R01 | Mechanisms of chronic visceral hyperalgesia | 09/04-03/06 335,362 |
“ | Allergan | Treatment for irritable bowel syndrome | 09/04-12/05 545,000 |
“ | GlaxoSmith K | Irritable bowel syndrome treatment | 09/04-09-07 360,000 |
“ | Allergan | New agents for IBS | 09/04-12/07 1,200,000 |
“ | NIH-NIDDK R01 | Sex hormones and visceral hypersensitivity | 04/08-03/13 1,800,000 |
“ | NIH-NIDDK R21 | Role of Microglia in Chronic Visceral Pain | 06/09-05/11 310,000 |
“ | NIH-NIDDK subcon | Spinal Microglial Mechanisms of Visceral Hypersensitivity (C. Saab PI) | 07/10-06/12 40,000 |
P. Beck, M.D./Ph.D. IBS student | NIH-NINDS F30 | Role of leptin in arousal | 07/09-06/13 150,000 |
A. Charlesworth, Ph.D. Neurobiol. (left UAMS) | Amer Heart | Role of Zar family proteins in M-phase control | 07/07-06/11 400,000 |
“ | UAMS-MREF | Genetic analysis of development | 01/07-12/07 15,000 |
“ | UAMS-COM | Regulation of M-phase by Zar family proteins | 11/06-12/07 15,000 |
G. Childs, Ph.D. Neurobiology | NIH-NICHD R01 | The significance of leptin signals to somatotropes and gonadotropes | 07/09-06/14 1,754,460 |
“ | NIH-NICHD R03 | Significance of Pituitary Leptin to Gonadotropes | 04/09-03/12 145,000 |
C. Cole, R.N., Ph.D.
Nursing (ret.) |
NIH-NINR R15 | Feasibility Study: Attention Measured in Alzheimer’s & Mild Cognitive Impairment. | 07/07-06/09 142,900 |
“ | NIH-NINR K23 | Sleep fragmentation and Attention in Alzheimer’s Disease | 07/06-06/11 283,838 |
“ | NIH-NINR | Tailored biobehavioral interventions in AD | 07/08-06/09 15,000 |
“ | Beverly Healthcare | Sleep research in AD | 07/08-06/09 31,481 |
J. Dornhoffer, M.D.
ENT |
Tinnitus Res Cons | Using PET-CT to Target and Validate Low-Frequency TMS as a Treatment for Tinnitus | 07/06-06/09 300,000 |
E. Garcia-Rill, Ph.D. Neurobiology | NIH-NINDS R01 | Central modulation of rhythms | 07/07-06/12 1,250,000 |
S. T. Griffin, Ph.D. Geriatrics | NIH-NIA P01 | Early events in Alzheimer pathogenesis | 04/09-03/14 6,066,664 |
R. W. Hall, M.D. Pediatrics | Medicaid | Telemedicine outreach utilizing collaborative health care | 05/08-04/13 1,458,826 |
“ | Mayday Fnd | AR Neonate electrical stimulation study | 11/08-10/10 399,929 |
A. Hayar, Ph.D. Neurobiology | NIH-NIDCD R03 | Synchronous bursting among juxtaglomerular neurons | 05/04-04/07 150,000 |
“ | NIH-NIDCD R01 | External tufted cells coordinate olfactory bulb activity | 07/05-06/10 1,000,000 |
“ | NIH-NINDS subcon | Contribution of EPL interneurons to olfaction (K. Hamilton, PI) | 04/08-03/12 150,000 |
“ | ABI | PSD95 scaffolding of vascular K+ channels in hypertension | 01/09-10/10 38,500 |
T. Kaiser, M.D. Pediatrics (left UAMS) | NIH-NICHD R01 | Permissive hypercapnea and IVH | 04/08-03/11 2,131,535 |
“ | NIH-NICHD R01 subcon | Gene targets for IVH
(L. Ment, PI) |
08/07-07/12 55,515 |
C. J. Kane, Ph.D. Neurobiology | NIH-NIAAA R01 | Microglia modulate ethanol impact on CNS development | 09/09-08/14 1,250,000 |
M. Kiaei, Ph.D. Neurobiology | NIH-NINDS R21 | Nrf2/ARE Pathway as a Therapeutic Target for Amyotrophic Lateral Sclerosis | 03/09-02/12 239,531 |
A, MacNicol, Ph.D.
Neurobiology |
NIH-NICHD R01 | Maternal gene regulation in early vertebrate development (Co-I) | 07/07-06/12 956,250 |
“ | AR Breast Cancer Res | Musashi2 expression as a novel breast cancer biomarker and therapeutic target (PI) | 07/12-06/13 66,481 |
M. Mennemeier, Ph.D.
Neurobiology |
NIH-NINDS R01 | Neglect and Neural Mechanisms of Magnitude Estimation | 04/05-03/10 1,784,732 |
“ | NIH-NICHD
R03 |
Rehabilitating strength perception after stroke | 12/07-11/09 100,000 |
“ | UAMS | Arousal-related deficits in AD | 07/06-06/07 15,000 |
“ | NIH-NCMRR R03 | Innovative treatments in spatial neglect | 04/05-03/06 142,000 |
“ | NIH-NICHD R21 | Identifying and treating arousal related deficits in neglect and dysphagia | 01/09-12/11 350,000 |
“ | UAMS TRI | Effect of rTMS on resting state activity in tinnitus | 10/11-09/12 49,986 |
“ | NIH-NIDCD R21 | Maintenace rTMS for chronic tinnitus relief | 04/12-03/14 401,719 |
S. Mulkey, M.D. Pediatrics | Thrasher Fnd (Site PI) | Neonatal Erythropoietin And Therapeutic Hypothermia Shortterm Outcome (Y. Wu PI) | 10/13-09/16 449,579 |
N. B. Reese, PT, Ph.D. Phys Ther (UCA) | NIH-NINDS R15 | Novel Treatment for Hyperreflexia following SCI | 12/08-11/10 198,517 |
C. Sheffer, Ph.D. Coll Pub Health (left UAMS) | Pfizer | Provider education program for treating tobacco use and dependence | 01/10-12/12 400,000 |
“ | NIH-NCI R03 | Treatment Modality and Socioeconomic Status in Treating Tobacco Dependence | 03/10-02/12 100,000 |
“ | NIH-NIMHD R01 | RITCh: Reducing socioeconomic disparities in tobacco dependence treatment outcomes | 07/12-06/17 966,740 |
F. J. Urbano, Ph.D. Vis Sci (UBA) | Guggenheim | Role of calcium channels in cocaine- and methylphenidate-induced alterations | 07/11-06/12 25,000 |
J. Watts, M.D./Ph.D. IBS student | NIH-NIDDK F30 | Novel Mechanisms of Visceral Pain: Functional Properties of Microglia | 07/10-06/13 160,000 |
M. Watts, M.D./Ph.D. IBS student | NIH-NIDDK F30 | Alpha2-adrenoceptors modulate TRPV4 and reduce inflammation-induced visceral pain | 07/10-06/13 160,000 |